EliMRothMD

PubMed

• 2 citations
  Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
  Eli M. Roth, John J.P. Kastelein, Christopher P. Cannon, Michel Farnier, James M. McKenney, A. Thomas DiCioccio, Aurélie Brunet, Garen Manvelian, William J. Sasiela, M...> ;Journal of Clinical Lipidology. 2020 Jul 25
• 12 citations
  Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.
  Jennifer G. Robinson, Michel Farnier, John J.P. Kastelein, Eli M. Roth, Marja-Riitta Taskinen, Helen M. Colhoun, Aurélie Brunet, A. Thomas DiCioccio, Guillaume Lecorps...> ;Journal of Clinical Lipidology. 2019 Nov 1
• 4 citations
  Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
  Dirk Müller-Wieland, Daniel J. Rader, Patrick M. Moriarty, Jean Bergeron, Gisle Langslet, Kausik K. Ray, Garen Manvelian, Desmond Thompson, Maja Bujas-Bobanovic, Eli M...> ;The Journal of Clinical Endocrinology and Metabolism. 2019 Nov 1
• 4 citations
  Alirocumab for low-density lipoprotein cholesterol lowering
  Eli M. Roth> ;Future Cardiology. 2019 Jan 1
• 28 citations
  PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety
  Eli M. Roth, Michael H. Davidson> ;Reviews in Cardiovascular Medicine. 2018 Jan 20
• Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD.
  Roth, E.,Moriarty, P. M.,Bergeron, J.,Langslet, G.,Manvelian, G.,Zhao, J.,Baccara-Dinet, M. T.,Rader, D. J.> ;Atherosclerosis. 2018 Jan 26
• Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia.
  Vallejo-Vaz, A. J.,Roth, E. M.,Hovingh, G. K.,Lee, L. V.,Gervasio, J.,Letierce, A.,Ray, K. K.> ;Atherosclerosis. 2018 Jan 26
• 4 citations
  A safety evaluation of evolocumab.
  Eli M. Roth> ;Expert Opinion on Drug Safety. 2018 Jan 1
• 63 citations
  Antidrug Antibodies in Patients Treated with Alirocumab
  Eli M. Roth, Anne C. Goldberg, Alberico L. Catapano, Albert Torri, George D. Yancopoulos, Neil Stahl, Aurélie Brunet, Guillaume Lecorps, Helen M. Colhoun> ;The New England Journal of Medicine. 2017 Mar 17
• 84 citations
  A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
  Eli M. Roth, Patrick M. Moriarty, Jean Bergeron, Gisle Langslet, Garen Manvelian, Jian Zhao, Marie T. Baccara-Dinet, Daniel J. Rader> ;Atherosclerosis. 2016 Nov 1
• 44 citations
  Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
  Dirk J. Blom, Michael J. Koren, Eli M. Roth, Maria Laura Monsalvo, C. Stephen Djedjos, Patric Nelson, Mary Elliott, Scott M. Wasserman, Christie M. Ballantyne, Rury R....> ;Diabetes, Obesity & Metabolism. 2017 Jan 1
• 29 citations
  Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 r...
  Peter P. Toth, Sara Hamon, Steven R. Jones, Seth S. Martin, Parag H. Joshi, Krishnaji R. Kulkarni, Poulabi Banerjee, Corinne Hanotin, Eli M. Roth, James M. McKenney> ;Lipids in Health and Disease. 2016 Feb 13
• 17 citations
  Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.
  Eli M. Roth> ;Future Cardiology. 2016 Jan 20
• 72 citations
  Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-blind, Randomized, Placebo-Controlled DESCARTES Study
  Dirk J. Blom, C. Stephen Djedjos, Maria Laura Monsalvo, Ian Bridges, Scott M. Wasserman, Rob Scott, Eli M. Roth> ;Circulation Research. 2015 Sep 25
• 42 citations
  Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceride...
  Richard L. Dunbar, Stephen J. Nicholls, Kevin C. Maki, Eli M. Roth, David G. Orloff, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H. Davidson> ;Lipids in Health and Disease. 2015 Sep 2
• 24 citations
  Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels.
  Eli M. Roth, Maja Bujas-Bobanovic, Michael J. Louie, Bertrand Cariou> ;Clinical Therapeutics. 2015 Sep 1
• 55 citations
  The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial
  Hamed Emami, Esad Vucic, Sharath Subramanian, Amr Abdelbaky, Zahi A. Fayad, Shuyan Du, Eli M. Roth, Christie M. Ballantyne, Emile R. Mohler, Michael E. Farkouh, Joonyo...> ;Atherosclerosis. 2015 Jun 1
• 61 citations
  FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity
  Joshua E. Lehrer-Graiwer, Parmanand Singh, Amr Abdelbaky, Esad Vucic, Magnus Korsgren, Amos Baruch, Jill Fredrickson, Nick Van Bruggen, Meina T. Tang, Björn Frendéus, ...> ;JACC. Cardiovascular Imaging. 2015 Apr 1
• 13 citations
  Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
  Michael J. Koren, Eli M. Roth, James M. McKenney, Daniel A. Gipe, Corinne Hanotin, Anne-Catherine Ferrand, Richard Wu, Robert Dufour> ;Postgraduate Medicine. 2015 Feb 24
• 51 citations
  ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.
  Eli M. Roth, James M. McKenney> ;Future Cardiology. 2015 Jan 21
• 8 citations
  ω-3 carboxylic acids for hypertriglyceridemia.
  Eli M. Roth> ;Expert Opinion on Pharmacotherapy. 2015 Jan 1
• 19 citations
  Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial
  Eliot A. Brinton, Uma Kher, Sukrut Shah, Christopher P. Cannon, Michael H. Davidson, Antonio M. Gotto, Tanya B. Ashraf, Christine McCrary Sisk, Hayes M. Dansky, Yale B...> ;Journal of Clinical Lipidology. 2015 Jan 1
• 41 citations
  Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
  Patrick M. Moriarty, Eli M. Roth, Adam Karns, Ping Ye, Shui-ping Zhao, Yuhua Liao, David M. Capuzzi, Harold E. Bays, Fumin Zhang, Shaowen Liu, Alan J. Reichman, Osvald...> ;Journal of Clinical Lipidology. 2014 Nov 1
• 162 citations
  Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dos...
  Daniel Gaudet, Dean J. Kereiakes, James M. McKenney, Eli M. Roth, Corinne Hanotin, Daniel A. Gipe, Yunling Du, Anne-Catherine Ferrand, Henry N. Ginsberg, Evan A. Stein> ;The American Journal of Cardiology. 2014 Sep 1
• 113 citations
  Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled anal...
  Evan A. Stein, Robert P. Giugliano, Michael J. Koren, Frederick J. Raal, Eli M. Roth, Robert M. Weiss, David R. Sullivan, Scott M. Wasserman, Ransi Somaratne, Jae B. K...> ;European Heart Journal. 2014 Sep 1
• Join now to see all